Tandem Meetings 2023 | Real-world study of tixagevimab/cilgavimab in pre-exposure prophylaxis for alloSCT recipients

Name: Real-world study of tixagevimab/cilgavimab in pre-exposure prophylaxis for alloSCT recipients
Uploaded: 2023-02-17T00:00:00Z
Duration: 2 min 25 s

Jaime Shahan • 17 Feb 2023

Tandem Meetings 2023

General Antibodies Cilgavimab Tixagevimab

Jaime Shahan, MPAS, PA-C, UT Southwestern Medical Center, Dallas, TX, comments on the results of a real-world study assessing the efficacy and safety of tixagevimab/cilgavimab (Txg/Cgv; Evusheld™) as pre-exposure prophylaxis in allogeneic stem cell transplant (alloSCT) recipients. Out of 18 patients who received Txg/Cgv, two developed COVID-19 and one required hospitalization. In addition, although two patients developed new onset graft-versus-host disease (GvHD) and two had progressive GvHD, further studies must be conducted to confirm whether this is associated with the use of Txg/Cgv. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.